drugset
Drugs / 68Ga-BBN-IRDye800CW
last change Dec 2018 re-read 3 minutes ago

68Ga-BBN-IRDye800CW

Diagnostic / imaging agent targets GRPR

Investigated by
Chinese Academy of Sciences · National Institute for Biomedical Imaging and Bioengineering (NIBIB) · Peking Union Medical College Hospital · Beijing Tiantan Hospital · Deling Li

Trials 2

today NCT03407781 · Ph 1 NCT02910804 · Ph 0
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT02910804 Nov 2015 → Dec 2018 glioblastoma Beijing Tiantan Hospital Unknown No outcome recorded
Phase 11 trial
Phase 1 NCT03407781 Jan 2016 → Aug 2018 glioma Deling Li Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as 68Ga-BBN-IRDye800CW ClinicalTrials.gov intervention name — accepted as the source's own label NCT02910804 ↗
1

NCT03407781 ↗
Modality Diagnostic / imaging agent “dual modality imaging probe 68Ga-BBN-IRDye800CW” NCT02910804 ↗
Route Intravenous “injected intravenously” NCT02910804 ↗
Target GRPR “GRPR targeting dual modality probe” NCT02910804 ↗